US3211614A - Enema-type laxative composition - Google Patents
Enema-type laxative composition Download PDFInfo
- Publication number
- US3211614A US3211614A US294151A US29415163A US3211614A US 3211614 A US3211614 A US 3211614A US 294151 A US294151 A US 294151A US 29415163 A US29415163 A US 29415163A US 3211614 A US3211614 A US 3211614A
- Authority
- US
- United States
- Prior art keywords
- laxative
- composition
- colon
- water
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008141 laxative Substances 0.000 title claims description 53
- 230000002475 laxative effect Effects 0.000 title claims description 51
- 239000000203 mixture Substances 0.000 title claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000004615 ingredient Substances 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 9
- 239000000600 sorbitol Substances 0.000 claims description 9
- 150000001447 alkali salts Chemical class 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 150000001261 hydroxy acids Chemical class 0.000 claims description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- 239000001630 malic acid Substances 0.000 claims description 5
- 235000011090 malic acid Nutrition 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 38
- 210000001072 colon Anatomy 0.000 description 24
- 235000011187 glycerol Nutrition 0.000 description 13
- 238000011835 investigation Methods 0.000 description 13
- 239000000080 wetting agent Substances 0.000 description 12
- 241000792859 Enema Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000007920 enema Substances 0.000 description 10
- 229940079360 enema for constipation Drugs 0.000 description 7
- 230000003444 anaesthetic effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 229940075560 sodium lauryl sulfoacetate Drugs 0.000 description 4
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 4
- -1 tetramethylbutylphenoxy Chemical group 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 229940124326 anaesthetic agent Drugs 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 229940095399 enema Drugs 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YUGZHQHSNYIFLG-UHFFFAOYSA-N N-phenylcarbamic acid [2-[anilino(oxo)methoxy]-3-(1-piperidinyl)propyl] ester Chemical compound C1CCCCN1CC(OC(=O)NC=1C=CC=CC=1)COC(=O)NC1=CC=CC=C1 YUGZHQHSNYIFLG-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- BZHXZJHJXDIDJU-UHFFFAOYSA-N formic acid;2-(2-methylpropylamino)ethyl 4-aminobenzoate Chemical compound OC=O.CC(C)CNCCOC(=O)C1=CC=C(N)C=C1 BZHXZJHJXDIDJU-UHFFFAOYSA-N 0.000 description 2
- 230000000266 injurious effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- CLWAXFZCVYJLLM-UHFFFAOYSA-N 1-chlorohexadecane Chemical compound CCCCCCCCCCCCCCCCCl CLWAXFZCVYJLLM-UHFFFAOYSA-N 0.000 description 1
- ARKDNMZXRXKLOV-UHFFFAOYSA-N 2-(2-methylpropylamino)ethyl 4-aminobenzoate;hydrochloride Chemical compound Cl.CC(C)CNCCOC(=O)C1=CC=C(N)C=C1 ARKDNMZXRXKLOV-UHFFFAOYSA-N 0.000 description 1
- SDNODXJEIFDIKF-UHFFFAOYSA-N 2-(pentylamino)ethyl 4-aminobenzoate;hydrochloride Chemical compound [Cl-].CCCCC[NH2+]CCOC(=O)C1=CC=C(N)C=C1 SDNODXJEIFDIKF-UHFFFAOYSA-N 0.000 description 1
- REUGYQBMHOOQKM-UHFFFAOYSA-N 2-[3-(2-chlorophenyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C=2C(=CC=CC=2)Cl)=C1 REUGYQBMHOOQKM-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-M 4-aminobenzoate Chemical compound NC1=CC=C(C([O-])=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 238000009606 cholecystography Methods 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229960002228 diperodon Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 238000001935 peptisation Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000007487 urography Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
Definitions
- the present invention generally relates to a novel and highly effective laxative composition of that type which is to be administered through the anus. More specifically the present invention pertains to a laxative composition which effects a complete removal of the colon contents without requiring large quantities of Water to be introduced ino the colon and without any risk of the fluid balance of the body being distributed. (For the purpose of this specification and claims the terms laxative composition and enema composition are considered to be substantially synonymous and equivalent.)
- X-ray investigations means both those investigations wherein X-rays, after having passsed through different parts of the body, are intercepted a: an image on a photographic plate, and such investigations wherein the passing rays are caused to strike upon a fluorescent surface on so-called irradiation.
- small enemas of a hypertonic aqueous solution of sodium phosphate are sometimes substituted for the large water enemas, the effect of these small enemas being based on an increase of the crystalloid osmotic pressure in the colon.
- these small enemas may have undesirable side effects if the solution diffuses through the wall of the colon and disturbs the fluid balance of the body.
- the main object of the present invention is to provide a laxative composition which is highly effective in the treatment of constipation.
- a second object of the invention is to provide a laxative composition to be used as an aid in connection with medical investigations wherein it is important to empty the colon as completely as possible.
- a third object of the invention is to provide a laxative composition adapted to be placed in a disposable container holding a quantity of laxative sufficient to effect a complete evacuation of the colon after having been administered through the anus.
- the present invention in its broadest scope, involves the preparation of laxative compositions containing as its essential active ingredients:
- a polyhydroxy alcohol having at least five hydroxyl groups the hexatols such as mannitol, sorbitol and dulcitol being preferred over the pentitols such as arabitol, xylitol and adonitol.
- the effect of the laxative composition in accordance with the present invention differs from that aimed at in previous enema compositions.
- the main purpose of our invention is to form a suspension of the colonic contents in their own water, which is accomplished by causing the laxative composition to penetrate into the colonic contents, which may be considered to be a precipitated swollen organic colloidal substance containing relatively large amounts of water. A peptization of the colloidal substance with the liberation of the water is thereby effected and the resulting smaller particles form a suspension with this water which leaves the colon during the emptying process.
- the laxative composition in accordance with our invention may be prepared in the form of a solution or it may be prepared so as to have an ointment-like appearance.
- the laxative composition in accordance with our invention has proved to be particularly effective for various types of colonic constipation.
- the subject matter of the present invention represents an important advance in the medical diagnostic field.
- laxative has also been used in connection with investigations other than X-ray examinations, wherein it is of importance that the colon should be carefully emptied.
- the laxative has proved to be a valuable aid for direct studies of the intestinal mucous membrane, for investigations of suspected tumors (biopsies) and for gynaecological examinations.
- pH of the laxative composition In order that the laxative composition in accordance with the invention may meet the requirement of being therapeutically acceptable, its pH-value should preferably not be too far away from the neutral point on each side thereof.
- a lower limit of pH-value 6 On the acid side, a lower limit of pH-value 6 is probably preferable, but it should be pointed out that somewhat lower pH-values may be used.
- pH-values lower than about 6 it may be necessary to add a local anaesthetic to the laxative composition so that pains shall not occur in the use thereof.
- a pH-val-ue of about 9 can be stated. In fact, it is preferable that a pI-I-value of about 8 should not be exceeded.
- pH-values higher than 9 could be used here and the disadvantages obtained compensated for by incorporating a local anaesthetic in a sufiicient amount to remove the risk of pain occurring when the laxative is used.
- laxative composition in accordance with this invention, those skilled in the art will readily appreciate that the laxative composition may also include a number of other ingredients to enhance the overall effectiveness of the laxative composition.
- wetting agents In the event that the laxative composition has a wetting agent incorporated therein the latter may be of either the anionic, the cationic or the nonionic type.
- anionic mention may be made of dioctyl sodium sulfosuccinate, sodium lauryl sulfoacetate, sodium lauryl sulfate, sodium tetnadecyl sulfate.
- cationic wetting agents mention may be made of the quaternary ammonium compounds which may be characterized as synthetic salts of organic, nitrogen-containing compounds.
- cationic wetting agents examples include benzalkonium chloride (alkylbenzyldimethylammonium chloride), benzethonium chloride, benzyldimethyl [2- (2-- /1,1,3,3 tetramethylbutylphenoxy/ethoxy)ethyl] ammoniumchlon'de, monohy-drate, cetyl pyridinium chloride (the monohydrate of the quaternary salt of pyridine and cetyl chloride), mefhylbenzethonium chloride, benzyldimethyl [2(2-/1,-1,3,3-tetramethylbutylcresoxy/ethoxy)ethyl] ammonium chloride.
- n-onionic Wetting agents mention may be made of esters of polyhydric alcohols and fatty acids, for example, polyoxyethylene sorbitan mono-oleate wetting agents that are marketed under the trade name Tween by the Atlas Powder Company.
- butethamine formate (2-isobutylaminoethyl p-aminobenzoate formate)
- mon-ocaine hydrochloride (2- isobutylaminoethyl p-aminobenzoa-te hydrochloride)
- percaine hydrochloride (2butoxy-N-/2-diethylaminoethyl/cinchoninamide), diothane hydrochloride (3-/'1-piperidyl/-1,2-propanedi-ol dicarbanila-te hydrochloride), diothane (3-/ l-piperidyl/ -l,'2-propanedio1 dicarbanilate), xylocaine hydrochloride (alpha-diethylamino-2,6-
- agents capable of stabilizing the pH in the pH range 7-9 mention may be made of 3-(trishydr-oxymethyl) aminomethane, N-dimethylleucylblycine, diethanolamine, triethanolamine.
- agents capable of stabilizing the pH in the 'nange.67 mention should be made of glycocoll, glycine, sodium bicarbonate, mixtures of sodium monophosphate and sodium diphosphate, borax. (See: Bates, Electrometric pH determinations, Theory and practice, 1954, pages 114-116).
- the content of the pH-stabilizing agent may amount to 10 percent, and does not usually exceed about 5 percent.
- Glycerol we have found that it is usually desirable to include glycerol in our laxative compositions in order to promote the solubility of the components of the laxative, particularly when the latter contains a wetting agent.
- Viscosity increasing agen t may also contain a viscosity increasing agent such as polysaccharides, for example, dextr-an, insulin, water soluble starch, pectin, gummi arabicum, carboxymethyl compounds of starch and cellulose; polypeptides and proteids, for example, gelatin; synthetic polymers, for example, polyvinylpyrrolidone.
- the content of the viscosity increasing agent may amo-unt to about 10 percent but does preferably not exceed about 5 percent.
- Percent Alkali salt of hydroxy acid 2 15 An .alcohol having at least five hydroxy ⁇ groups :10-80 Water 5-70 Glycerol 0-15 Wetting agent 0-5 The effect of the glycerol begins at the limit 0.02 percent and that of the wetting agent at 0.01 percent. At 0.2 percent the effect of the glycerin is still more remarkable.
- Percent Alkali salt of hydroxy acid 4-10 An alcohol having at least five hydroxy groups 20-65 Water 8-40 Glycerol 00 2- 12 Wetting agent 0.01-3
- the laxative compositions referred to contain the different ingredients listed in the .tables in a total amount of at least percent, and most preferably at least '95 percent.
- Additional substances may be present in percentages preferably amounting to not more than 10 percent and most preferably not more than 5 percent.
- composition the pH of which was 7.4, was particularly effective as a laxative and quite suitable for medical investigation, wherein it is of importance that the colon should be carefully emptied. Also, the composition is easily endurable Without pain resulting from its use.
- G Sodium citrate (three-basic) 50 Dioctyl sodium sulfosuccinate 20 Glycerol 50 Sorbitol (70 percent aqueous solution) to 1000
- the solution with a pH-value of 7.2 was placed in disposable containers with 10 ml. in each unit.
- the quantity in most cases proved to be sufiicient to remove the most severe constipation in the colon and removed the contents of the colon completely so that the organs in the vicinity of the colon could be diagnosed without disturbances due to contrast produced by faces in the colon.
- EXAMPLE 4 An effective and useful laxative composition was made up from the following ingredients:
- compositions of this invention function as effective laxatives when administered in only a very small quantity (e.g. 2-20-ml. and preferably 510 ml.), whereas the laxative products available on the market prior to this invention have had to employ much greater quantities in order to obtain the desired result.
- a very small quantity e.g. 2-20-ml. and preferably 510 ml.
- the laxative products available on the market prior to this invention have had to employ much greater quantities in order to obtain the desired result.
- the fact that the compositions of this invention function as effective laxatives in small dosages of only 2-20 ml. is believed to be convincing evidence that the particular combination of ingredients employed produces an unexpected result.
- the claims which follow make mention of a highly effective and useful dosage range, there is no intention that the claims should be restricted thereto because the invention is believed to reside in the discovery of the particular combination of ingredients which makes the use of very small dosages possible.
- the laxative compositions prepared in accordance with the above examples were found to completely remove colonic contents without requiring large quantities of water to be introduced into the colon and without disturbing the fluid balance of the body.
- composition which is highly effective as a laxative when administered in volumes of only 2-20 ml., consisting essentially of the following ingredients:
- a highly effective therapeutically acceptable laxative composition as set forth in claim 1 wherein the alcohol is sorbitol.
- a highly eifective therapeutically acceptable laxative composition as set forth in claim 1 wherein the said alkali salt is sodium citrate.
- composition which is highly efiective as a laxative when administered in a volume of about 6 milliliters, consisting essentially of:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
United States Patent 3,211,614 ENEMA-TYPE LAXATIVE COMPOSITION Paul Gunnar Embring, Uppsala, and Per Ove Mattsson,
Stockholm, Sweden, assignors to Aktiebolaget Pharmacia, a company of Sweden No Drawing. Filed July 10, 1963, Ser. No. 294,151
6 Claims. (Cl. 16756) This is a continuation-in-part of our application Serial No. 52,866, filed August 30, 1960, now abandoned.
The present invention generally relates to a novel and highly effective laxative composition of that type which is to be administered through the anus. More specifically the present invention pertains to a laxative composition which effects a complete removal of the colon contents without requiring large quantities of Water to be introduced ino the colon and without any risk of the fluid balance of the body being distributed. (For the purpose of this specification and claims the terms laxative composition and enema composition are considered to be substantially synonymous and equivalent.)
BACKGROUND In order to carry out a number of medical investigations it is very important that the colon be emptied as completely as possible. This particularly applies with respect to the visual inspection of the rectum and sigmoideum for diagnostic purposes. It is most important for X-ray investigations of the colon and rectum, in which interpretation of the images obtained is made more difficult, or impossible, by contrast-producing faeces. Other types of X-ray investigations in which the possibilities of interpreting the X-ray images are also decreased due to contrast-producing intestinal contents, are urography, hysterosal-pingography, cholecystography and pelvicarteriography.
The term X-ray investigations is used herein means both those investigations wherein X-rays, after having passsed through different parts of the body, are intercepted a: an image on a photographic plate, and such investigations wherein the passing rays are caused to strike upon a fluorescent surface on so-called irradiation.
In order to effect an emptying of the colon, water enemas have previously been employed wherein large quantities of water, often containing various additives, are introduced into the colon to induce its emptying, the contents of the colon being expelled in the form of a suspension.
However, in the last few years it has been found that the introduction of too large a quantity of water in enemas may be injurious and cases of so-called water poisoning, particularly in the field of child nursing, have been reported in the professional press. (See, for example, Lancet, 1959:1/7072, pages 559560, Hazard of Water Enemas.) It may further be mentioned that in connection with such X-ray investigations of the urinary tract, which are based on the excretion of contrast agents, any supply of water to the body may result in the dilution of the contrast agents, and for this reason the supply of liquids should be as small as possible.
In view of these hazards and disadvantages small enemas of a hypertonic aqueous solution of sodium phosphate are sometimes substituted for the large water enemas, the effect of these small enemas being based on an increase of the crystalloid osmotic pressure in the colon. However, these small enemas may have undesirable side effects if the solution diffuses through the wall of the colon and disturbs the fluid balance of the body.
OBJECTS The main object of the present invention is to provide a laxative composition which is highly effective in the treatment of constipation.
A second object of the invention is to provide a laxative composition to be used as an aid in connection with medical investigations wherein it is important to empty the colon as completely as possible.
A third object of the invention is to provide a laxative composition adapted to be placed in a disposable container holding a quantity of laxative sufficient to effect a complete evacuation of the colon after having been administered through the anus.
These and other objects and advantages will be evident after reading the following description.
THE PRESENT INVENTION In accordance with this invention we have found a therapeutically acceptable laxative which overcomes the disadvantages referred to above and effects a complete removal of the colon contents without requiring large quantities of water to be introduced into the colon and without any risk of the fluid balance of the body being disturbed.
The present invention, in its broadest scope, involves the preparation of laxative compositions containing as its essential active ingredients:
(a) An alkali salt of an aliphatic polybasic organic hydroxy acid selected from the group consisting of citric acid, tartaric acid, malic acid and ascorbic acid; and
(b) A polyhydroxy alcohol having at least five hydroxyl groupsthe hexatols such as mannitol, sorbitol and dulcitol being preferred over the pentitols such as arabitol, xylitol and adonitol.
In principle, the effect of the laxative composition in accordance with the present invention differs from that aimed at in previous enema compositions.
The main purpose of our invention is to form a suspension of the colonic contents in their own water, which is accomplished by causing the laxative composition to penetrate into the colonic contents, which may be considered to be a precipitated swollen organic colloidal substance containing relatively large amounts of water. A peptization of the colloidal substance with the liberation of the water is thereby effected and the resulting smaller particles form a suspension with this water which leaves the colon during the emptying process.
The laxative composition in accordance with our invention may be prepared in the form of a solution or it may be prepared so as to have an ointment-like appearance.
The laxative composition in accordance with our invention has proved to be particularly effective for various types of colonic constipation. By the same method it is also possible to effect a complete emptying of the colon without any injurious effects so that X-ray investigations 3 of the colon and surrounding organs can be carried out without any risks of the presence of confusing contrasts on the X-ray images obtained. In this respect the subject matter of the present invention represents an important advance in the medical diagnostic field.
This type of laxative has also been used in connection with investigations other than X-ray examinations, wherein it is of importance that the colon should be carefully emptied. Thus, the laxative has proved to be a valuable aid for direct studies of the intestinal mucous membrane, for investigations of suspected tumors (biopsies) and for gynaecological examinations.
pH of the laxative composition In order that the laxative composition in accordance with the invention may meet the requirement of being therapeutically acceptable, its pH-value should preferably not be too far away from the neutral point on each side thereof. On the acid side, a lower limit of pH-value 6 is probably preferable, but it should be pointed out that somewhat lower pH-values may be used. However, when using pH-values lower than about 6, it may be necessary to add a local anaesthetic to the laxative composition so that pains shall not occur in the use thereof. As a preferable upper limit on the alkaline side of the neutral point, a pH-val-ue of about 9 can be stated. In fact, it is preferable that a pI-I-value of about 8 should not be exceeded. However, pH-values higher than 9 could be used here and the disadvantages obtained compensated for by incorporating a local anaesthetic in a sufiicient amount to remove the risk of pain occurring when the laxative is used.
OTHER INGREDIENTS Although the essential ingredients of a laxative composition in accordance with this invention have been set forth above, those skilled in the art will readily appreciate that the laxative composition may also include a number of other ingredients to enhance the overall effectiveness of the laxative composition.
Wetting agents.-In the event that the laxative composition has a wetting agent incorporated therein the latter may be of either the anionic, the cationic or the nonionic type. As anionic mention may be made of dioctyl sodium sulfosuccinate, sodium lauryl sulfoacetate, sodium lauryl sulfate, sodium tetnadecyl sulfate. As cationic wetting agents mention may be made of the quaternary ammonium compounds which may be characterized as synthetic salts of organic, nitrogen-containing compounds. Examples of cationic wetting agents are benzalkonium chloride (alkylbenzyldimethylammonium chloride), benzethonium chloride, benzyldimethyl [2- (2-- /1,1,3,3 tetramethylbutylphenoxy/ethoxy)ethyl] ammoniumchlon'de, monohy-drate, cetyl pyridinium chloride (the monohydrate of the quaternary salt of pyridine and cetyl chloride), mefhylbenzethonium chloride, benzyldimethyl [2(2-/1,-1,3,3-tetramethylbutylcresoxy/ethoxy)ethyl] ammonium chloride. As n-onionic Wetting agents mention may be made of esters of polyhydric alcohols and fatty acids, for example, polyoxyethylene sorbitan mono-oleate wetting agents that are marketed under the trade name Tween by the Atlas Powder Company.
Anaesthetics.- Loca'l anaesthetics in an amount within the range of about 0.5- may be suitably incorporated in the laxative composition. As examples thereof should be mentioned butethamine formate (2-isobutylaminoethyl p-aminobenzoate formate), mon-ocaine hydrochloride (2- isobutylaminoethyl p-aminobenzoa-te hydrochloride), nu-
percaine hydrochloride (2butoxy-N-/2-diethylaminoethyl/cinchoninamide), diothane hydrochloride (3-/'1-piperidyl/-1,2-propanedi-ol dicarbanila-te hydrochloride), diothane (3-/ l-piperidyl/ -l,'2-propanedio1 dicarbanilate), xylocaine hydrochloride (alpha-diethylamino-2,6-|acetoxylidide hydrochloride) amylsine hydrochloride (Z-amylaminoethyl p aminobenzoate hydrochloride), metyc-aine hydrochloride (3-/2-methyll-piperidyl/propyl :benzoate hydrochloride) pH stabilizers.Minor amounts of substances capable of stabilizing the pH of the laxative composition within the desired pH limits of 6 and 9 may be added. As examples of agents capable of stabilizing the pH in the pH range 7-9 mention may be made of 3-(trishydr-oxymethyl) aminomethane, N-dimethylleucylblycine, diethanolamine, triethanolamine. As examples of agents capable of stabilizing the pH in the 'nange.67 mention should be made of glycocoll, glycine, sodium bicarbonate, mixtures of sodium monophosphate and sodium diphosphate, borax. (See: Bates, Electrometric pH determinations, Theory and practice, 1954, pages 114-116). The content of the pH-stabilizing agent may amount to 10 percent, and does not usually exceed about 5 percent.
Glycerol.We have found that it is usually desirable to include glycerol in our laxative compositions in order to promote the solubility of the components of the laxative, particularly when the latter contains a wetting agent.
Viscosity increasing agen t.The laxative compositions may also contain a viscosity increasing agent such as polysaccharides, for example, dextr-an, insulin, water soluble starch, pectin, gummi arabicum, carboxymethyl compounds of starch and cellulose; polypeptides and proteids, for example, gelatin; synthetic polymers, for example, polyvinylpyrrolidone. The content of the viscosity increasing agent may amo-unt to about 10 percent but does preferably not exceed about 5 percent.
AMOUNTS OF LAXATIVE COMPONENTS The percentages of the different ingredients of the laxative compositions in accordance with the invention may vary within the limits evident from the following table:
Percent Alkali salt of hydroxy acid 2 15 An .alcohol having at least five hydroxy} groups :10-80 Water 5-70 Glycerol 0-15 Wetting agent 0-5 The effect of the glycerol begins at the limit 0.02 percent and that of the wetting agent at 0.01 percent. At 0.2 percent the effect of the glycerin is still more remarkable.
Preferable limits with respect to the percentages are set forth in the following table:
Percent Alkali salt of hydroxy acid 4-10 An alcohol having at least five hydroxy groups 20-65 Water 8-40 Glycerol 00 2- 12 Wetting agent 0.01-3
Preferably the laxative compositions referred to contain the different ingredients listed in the .tables in a total amount of at least percent, and most preferably at least '95 percent.
Additional substances may be present in percentages preferably amounting to not more than 10 percent and most preferably not more than 5 percent.
EXAMPLE S The following examples are illustrative of preferred embodiments of the present invention. It should be understood that these examples are not intended to limit the invention and that obvious changes may be made by those skilled in the art without changing the essential characteristics and the basic concept of the invention. The parts and percentages are by weight, the temperature is room temperature and the pressure is atmospheric unless otherwise indicated.
EXAMPLE 1 A laxative composition was made up by mixing together the following ingredients:
G. Sodium citrate (three-basic) Sodium lauryl sulfoacetate 2 Glycerol 10 Water 10 Sorbitol (70 percent aqueous solution) to 100 This composition, the pH of which was 7.4, proved to be a particularly effective laxative and as such it was valuable for medical investigations wherein the colon had to be emptied.
The above composition, the pH of which was 7.4, was particularly effective as a laxative and quite suitable for medical investigation, wherein it is of importance that the colon should be carefully emptied. Also, the composition is easily endurable Without pain resulting from its use.
EXAMPLE 3 A laxative composition was made up by mixing the following ingredients:
G. Sodium citrate (three-basic) 50 Dioctyl sodium sulfosuccinate 20 Glycerol 50 Sorbitol (70 percent aqueous solution) to 1000 The solution with a pH-value of 7.2 was placed in disposable containers with 10 ml. in each unit. The quantity in most cases proved to be sufiicient to remove the most severe constipation in the colon and removed the contents of the colon completely so that the organs in the vicinity of the colon could be diagnosed without disturbances due to contrast produced by faces in the colon.
EXAMPLE 4 An effective and useful laxative composition was made up from the following ingredients:
Sodium ascorbate 7.5 Mannitol 25.0 Water, sufficient to make 100 EXAMPLE 5 An effective and useful laxative composition was made up from the following ingredients:
G. Sodium potassium tartrate 9 Polysorbate 20 (Tween 20) 1 Sorbitol 60 Water, sufficient to make 100 EXAMPLE 6 An effective and useful laxative composition was made up from the following ingredients:
Malic acid 6.5 Sodium bicarbonate 4 Benzethonium chloride 0.05 Glycerol 5 Polyalkohol-Mischung PA 70 (viscous aqueous solution of sorbitol and xylitol) sufficient to make 100 6 EXAMPLE 7 Sodium lauryl sulfoacetate 64.8% active by weight 1.09 Sorbic acid 0.078 Glycerol 9.77 Sodium citrate 7.03 Sorbitol (70% aqueous byweight) 69.77 Distilled water to make 100 A six milliliter quantity of the above composition was found to be very effective as a laxative when packaged in a small plastic disposable unit.
An important characteristic of the compositions of this invention is that they function as effective laxatives when administered in only a very small quantity (e.g. 2-20-ml. and preferably 510 ml.), whereas the laxative products available on the market prior to this invention have had to employ much greater quantities in order to obtain the desired result. The fact that the compositions of this invention function as effective laxatives in small dosages of only 2-20 ml. is believed to be convincing evidence that the particular combination of ingredients employed produces an unexpected result. However, whereas the claims which follow make mention of a highly effective and useful dosage range, there is no intention that the claims should be restricted thereto because the invention is believed to reside in the discovery of the particular combination of ingredients which makes the use of very small dosages possible.
The laxative compositions prepared in accordance with the above examples were found to completely remove colonic contents without requiring large quantities of water to be introduced into the colon and without disturbing the fluid balance of the body.
Whenever the expression consisting essentially of is used in the attached claims it is intended to refer to the components which are essential to the composition, namely an alkali salt of an aliphatic polybasic hydroxy acid selected from the group consisting of citric acid, malic acid, tartaric acid and ascorbic acid and a polyhydric alcohol having at least 5 hydroxyl groups, and the expression does not exclude other components from the composition which do not render it unsuitable as a laxative or enema, such as Wetting agents, water, glycerol, viscosity increasing agents, pH stabilizers, anaesthetics, etc.
Those skilled in the chemical arts, and particularly in the art to which this invention pertains, will readily appreciate that many modifications of the basic invention set forth here are possible. For example, it would not involve invention to try closely related compounds in view of the present broad disclosure or in trying amounts different than those disclosed. All such obvious modifications would not avoid infringement under the well known doctrine of equivalents.
What is claimed is:
1. A composition which is highly effective as a laxative when administered in volumes of only 2-20 ml., consisting essentially of the following ingredients:
(a) an alkali salt of an aliphatic polybasic hydroxy acid selected from the group consisting of citric acid, malic acid, tartaric acid and ascorbic acid-2 to 15%,
(b) an alcohol selected from the group consisting of manitol, sorbitol, dulcitol, arabitol, xylitol and adonitoll0 to (c) water--5 to 70%.
2. A highly effective therapeutically acceptable laxative composition as set forth in claim 1, containing in addition glycerol.
3. A highly effective therapeutically acceptable laxative composition as set forth in claim 1, containing in addition a wetting agent.
4. A highly effective therapeutically acceptable laxative composition, as set forth in claim 1 wherein the alcohol is sorbitol.
5. A highly eifective therapeutically acceptable laxative composition, as set forth in claim 1 wherein the said alkali salt is sodium citrate.
6. A composition which is highly efiective as a laxative when administered in a volume of about 6 milliliters, consisting essentially of:
Percent Sodium lauryl sulfoacetate (64.8% by weight)..- 1.09 Sorbic acid .078
Glycerol 9.77
Sodium citrate 7.03
References Cited by the Examiner Jordan-Modern Drug Encyclopedia, 7th ed., February 1958, pages 1033 and 1181, Drug Publications Inc., New York.
JULIAN S. LEVITT, Primary Examiner.
FRANK CACCIAPAGLIA, JR., Examiner.
Claims (1)
1. A COMPOSITION WHICH IS HIGHLY EFFECTIVE AS A LAXATIVE WHEN ADMINISTERED IN VOLUMES OF ONLY 2-20 ML., CONSISTING ESSENTIALLY OF THE FOLLOWING INGREDIENTS: (A) AN ALKALI SALT OF AN ALIPHATIC POLYBASIC HYDROXY ACID SELECTED FROM THE GROUP CONSISTING OF CITRIC ACID, MALIC ACID, TARTARIC ACID AND ASCORBIC ACID -2 TO 15%, (B) AN ALCOHOL SELECTED FROM THE GROUP CONSISTING OF MANITOL, SORBITOL, DULCITOL, ARABITOL, XYLITOL AND ADONITOL - 10 TO 80%, (C) WATER - 5 TO 70%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US294151A US3211614A (en) | 1963-07-10 | 1963-07-10 | Enema-type laxative composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US294151A US3211614A (en) | 1963-07-10 | 1963-07-10 | Enema-type laxative composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US3211614A true US3211614A (en) | 1965-10-12 |
Family
ID=23132112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US294151A Expired - Lifetime US3211614A (en) | 1963-07-10 | 1963-07-10 | Enema-type laxative composition |
Country Status (1)
Country | Link |
---|---|
US (1) | US3211614A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0436061A1 (en) * | 1988-07-13 | 1991-07-10 | Roussel Morishita Co., Ltd. | Bowel lavage composition |
US5274001A (en) * | 1987-12-24 | 1993-12-28 | Borody Thomas J | Orthostatic lavage solutions |
US5710183A (en) * | 1995-07-14 | 1998-01-20 | Halow; George M. | Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent |
US6514537B1 (en) | 2000-06-02 | 2003-02-04 | Cumberland Swan Holdings, Inc. | Magnesium citrate solution |
US20040115282A1 (en) * | 2002-10-09 | 2004-06-17 | Keiser Dale A. | Gelled laxative compositions |
US20070086978A1 (en) * | 2002-10-25 | 2007-04-19 | Norgine Europe Bv | Colon cleansing compositions and methods |
WO2006138571A3 (en) * | 2005-06-16 | 2008-07-31 | Mohammed Saeed | Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance |
US20100178668A1 (en) * | 2002-06-20 | 2010-07-15 | Vision Biosystems Limited | Biological reaction apparatus with draining mechanism |
US20110015268A1 (en) * | 2007-12-07 | 2011-01-20 | Ferring International Center S.A. | Pharmaceutical composition |
US8999313B2 (en) | 2012-09-11 | 2015-04-07 | Norgine Bv | Compositions |
US20150342937A1 (en) * | 2013-10-17 | 2015-12-03 | Yoon Sik Kang | Bowel cleansing composition |
US9592252B2 (en) | 2011-03-11 | 2017-03-14 | Norgine Bv | Colonoscopy—preparation |
-
1963
- 1963-07-10 US US294151A patent/US3211614A/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
None * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5274001A (en) * | 1987-12-24 | 1993-12-28 | Borody Thomas J | Orthostatic lavage solutions |
EP0436061A1 (en) * | 1988-07-13 | 1991-07-10 | Roussel Morishita Co., Ltd. | Bowel lavage composition |
US5077048A (en) * | 1988-07-13 | 1991-12-31 | Morishita Pharmaceutical Co., Ltd. | Bowel lavage composition |
US5710183A (en) * | 1995-07-14 | 1998-01-20 | Halow; George M. | Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent |
US6514537B1 (en) | 2000-06-02 | 2003-02-04 | Cumberland Swan Holdings, Inc. | Magnesium citrate solution |
US20100178668A1 (en) * | 2002-06-20 | 2010-07-15 | Vision Biosystems Limited | Biological reaction apparatus with draining mechanism |
US9029154B2 (en) * | 2002-06-20 | 2015-05-12 | Leica Biosystems Melbourne Pty Ltd | Fill fluid for biological reaction apparatus with draining mechanism |
US20040115282A1 (en) * | 2002-10-09 | 2004-06-17 | Keiser Dale A. | Gelled laxative compositions |
US20070086978A1 (en) * | 2002-10-25 | 2007-04-19 | Norgine Europe Bv | Colon cleansing compositions and methods |
US20070098764A1 (en) * | 2002-10-25 | 2007-05-03 | Norgine Europe Bv | Colon cleansing compositions and methods |
US7658914B2 (en) | 2002-10-25 | 2010-02-09 | Norgine Bv | Colon cleansing compositions |
US20100086624A1 (en) * | 2002-10-25 | 2010-04-08 | Norgine Bv | Colon cleansing compositions and methods |
WO2006138571A3 (en) * | 2005-06-16 | 2008-07-31 | Mohammed Saeed | Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance |
US20090220553A1 (en) * | 2005-06-16 | 2009-09-03 | Mohammed Saeed | Composition and Method for Inhibiting, Preventing, or Ameliorating Complications Associated With Ingestion of a Medicinal, Chemical, or Biological Substance or Agent |
EP2371394A1 (en) * | 2005-06-16 | 2011-10-05 | Mohammed Saeed | Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent |
US8263561B2 (en) | 2005-06-16 | 2012-09-11 | Amana Pharmaceuticals Corp. | Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent |
US8637570B2 (en) * | 2007-12-07 | 2014-01-28 | Ferring International Center S.A. | Pharmaceutical composition |
US20110015268A1 (en) * | 2007-12-07 | 2011-01-20 | Ferring International Center S.A. | Pharmaceutical composition |
US10646512B2 (en) | 2011-03-11 | 2020-05-12 | Norgine Bv | Colonoscopy - preparation |
US11529368B2 (en) | 2011-03-11 | 2022-12-20 | Norgine Bv | Colonoscopy—preparation |
US10792306B2 (en) | 2011-03-11 | 2020-10-06 | Norgine Bv | Colonoscopy—preparation |
US9592252B2 (en) | 2011-03-11 | 2017-03-14 | Norgine Bv | Colonoscopy—preparation |
US10780112B2 (en) | 2011-03-11 | 2020-09-22 | Norgine Bv | Colonoscopy-preparation |
US9326969B2 (en) | 2012-09-11 | 2016-05-03 | Norgine Bv | Compositions |
US10016504B2 (en) | 2012-09-11 | 2018-07-10 | Norgine Bv | Compositions |
US9707297B2 (en) | 2012-09-11 | 2017-07-18 | Norgine Bv | Compositions |
US8999313B2 (en) | 2012-09-11 | 2015-04-07 | Norgine Bv | Compositions |
US10918723B2 (en) | 2012-09-11 | 2021-02-16 | Norgine Bv | Colon cleansing compositions and methods of use |
US12083179B2 (en) | 2012-09-11 | 2024-09-10 | Norgine Bv | Colon cleansing compositions and method of use |
US10973808B2 (en) | 2013-10-17 | 2021-04-13 | Yoon Sik Kang | Bowel cleansing composition |
US20150342937A1 (en) * | 2013-10-17 | 2015-12-03 | Yoon Sik Kang | Bowel cleansing composition |
US12310957B2 (en) | 2013-10-17 | 2025-05-27 | Yoon Sik Kang | Bowel cleansing composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3211614A (en) | Enema-type laxative composition | |
US4690823A (en) | Ibuprofen-containing soft gelatin capsules and process for preparing same | |
CN103041311B (en) | Baofukang suppository with expansion carrier | |
JP3706147B2 (en) | Non-aqueous colonic laxative formulation | |
DE69624711T2 (en) | MEANS FOR THE REINFORCEMENT OF POLAR MEDICINAL PRODUCTS FROM THE COLON | |
JP4579411B2 (en) | Local hormone composition with systemic action | |
US4772473A (en) | Nitrofurantoin dosage form | |
DE769938T1 (en) | Multi-layer capsules with a silicone resin filling | |
Barrowman et al. | Diarrhoeae in thyroid medullary carcinoma: role of prostaglandins and therapeutic effect of nutmeg. | |
EA004443B1 (en) | Pharmaceutical formulation for controlled release of ciprofloxacin for one administration per day | |
JPH11506432A (en) | Bisacodyl dosage form for colon delivery | |
WO2003015745A1 (en) | Expandable gastric retention device | |
JP4818587B2 (en) | Ibuprofen solution for hard shell capsules | |
JPH10158169A (en) | Pharmaceutical formulation containing trospium chloride, its preparation and use | |
KR19990087196A (en) | Contrast medium | |
DK171716B1 (en) | Process for the preparation of a complex of carrageenan and emepronium, doxycycline or propranolol | |
Morales et al. | A Viscous, Water-soluble Contrast Preparation: Preliminary Report | |
JPS63166832A (en) | Solution for nose | |
US3937800A (en) | Bronchographic x-ray contrast method | |
US2841526A (en) | Fatty acid-resin adsorption product | |
JP3122478B2 (en) | Lower gastrointestinal release oral formulation | |
JPS6140647B2 (en) | ||
US3733400A (en) | Digestive tract protecting compositions | |
Johnson et al. | LXXXV Toxicity of Bronchographic Contrast Media an Experimental Investigation | |
DE69416034T2 (en) | Pharmaceutical preparation for rectal administration of pharmacologically active compounds |